107 results about "Salbutamol sulfate" patented technology

The invention provides an oral solution containing ambroxol hydrochloride and salbutamol sulfate, and belongs to the technical field of medicines. An auxiliary material of the oral solution mainly comprises preservatives and corrigents. The oral solution is used for treating respiratory system diseases such as acute and chronic bronchitis, asthmatoid bronchitis and bronchial asthma, has a simple prescription, a good medication effect and a good taste, and is quick in response.

Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles or formulations. In one embodiment, an inhaler contains an aerosol formulation containing a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm. The particles may be suspended in a nonsolvent hydrofluorocarbon fluid vehicle (e.g., HFA 134a or 227ea) at a concentration within a range from about 0.2% w/v to about 5% w/v. The formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the vehicle. The particulate active substance may contain salmeterol xinafoate, budesonide, salbutamol sulfate, dihydroergotamine mesylate, risperidone-(9-hydroxy)-palmitate, bromocriptine mesylate, or derivatives thereof. In some examples, the active substance is dihydroergotamine mesylate.

The invention belongs to the technical field of medicines. The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for preventing and treating COVID-19 (diseases caused by novel coronaviruses) and a preparation method thereof. The pharmaceutical composition comprises active ingredients of mycobacterium vaccae for injection and salbutamol sulfate, and the weight ratio of the mycobacterium vaccae for injection to the salbutamol sulfate is 1: (50-200). The medicine prepared from the medicine composition can adopt an aerosol inhalation treatment mode, and through short-term aerosol inhalation, the compliance of a patient can be improved by providing the medicine with a specific purpose for the patient, so that the patient can take the medicine conveniently, and the medical cost is reduced. The pharmaceutical composition for preventing and treating COVID-19 disclosed by the invention has the advantages that the COVID-19 can be effectively prevented and treated; severe or critical symptoms of patients are relieved, nucleic acid negative conversion time is shortened by about 4 days averagely, treatment time is correspondingly shortened, other respiratory virus infections can be prevented and treated nonspecifically, and a new way and scheme are provided for clinical prevention and treatment of COVID-19 and respiratory virus infections.

The invention discloses a detection method of salbutamol sulfate-related substances. The detection method qualitatively or quantitatively detects the salbutamol sulfate-related substances with high performance liquid chromatography; detection conditions comprise a chromatographic column: octyl-bonded silica gel column, a detection wavelength: 210-400 nm, and mobile phases comprising a mobile phaseA and a mobile phase B, wherein the mobile phase A is an aqueous phase containing a buffer solution and having pH of 1.5-4.0, further having pH of 2.0-3.0; the mobile phase B mainly comprises methanol or acetonitrile; the mobile phases are eluted by gradient elution; and detection steps are as follows: (1) preparing a test substance solution and a reference substance solution; and (2) respectively sampling and detecting the test solution and the reference solution. The detection method of the salbutamol sulfate-related substances adopted by the invention can ensure effective separation of therelated substances.

The invention provides a tablet containing ambroxol hydrochloride and salbutamol sulfate, and belongs to the technical field of medicines. The tablet provided by the invention mainly comprises the following auxiliary materials: a filler, a disintegrating agent, a lubricant and an adhesive. The tablet provided by the invention is capable of treating diseases of a respiratory system, such as acute and chronic bronchitis, asthmatic bronchitis and bronchial asthma; sputum is easy to cough up when trachea is expanded; the tablet is simple in prescription, and good in curative effect; and the preparation technology is suitable for industrialized mass production.

The invention relates to the field of medicinal preparations, in particular to salbutamol sulfate sustained-release aerosol of micropowder for inspiration and a preparation method thereof. The invention is characterized in that the salbutamol sulfate sustained-release aerosol of micropowder for inspiration consists of salbutamol sulfate, polyhydroxyl sugar alcohol, a release sustaining material and amino acid. On the basis of the conventional aerosol of micropowder for inspiration, the sustained-release aerosol of micropowder for inspiration is prepared by adding certain materials. The obtained product has in-bronchus sustained-release performance, has high dissolubility, high bulk density, good angle of repose and high atomization performance and can prevent absorbing moisture.

The invention relates to a synthetic method for superfine sulfuric acid and salbutamol through using salbutamol and sulfuric acid as reactants, dissolving salbutamol into inert organic solvent, controlling the process operation parameters of the reaction, separating out salbutamol sulfate crystallization, filtering, scouring and drying to obtain the end product.

The invention relates to buccal tablets taking salbutamol sulfate and ambroxol hydrochloride as main active ingredients and a preparation method thereof, and aims to provide a new preparation, namely salbutamol sulfate and ambroxol hydrochloride buccal tablets, for the vast number of patients and medical workers. The preparation has quick response, can improve the bioavailability of medicaments, give full play to the treatment effects of the medicaments and reduce adverse reactions, is convenient for children to swallow and for old people to take with reduced dosage, and is convenient to carry, store and transport. The preparation method is simple and suitable for mass production. In the method, the buccal tablets are prepared by adding some specific types of auxiliary materials in certain proportions into the salbutamol sulfate and ambroxol hydrochloride serving as the active ingredients according to the conventional technique of pharmaceutical engineering.

The invention relates to pills taking salbutamol sulfate and ambroxol hydrochloride as main active ingredients and a preparation method thereof, and aims to provide a new preparation, namely salbutamol sulfate and ambroxol hydrochloride pills, for the vast number of patients and medical workers. The preparation can improve the bioavailability of medicaments, give full play to the treatment effects of the medicaments and reduce adverse reactions, is convenient for children to swallow and for old people to take with reduced dosage, and is convenient to carry, store and transport. The preparation method is simple and suitable for mass production. In the method, the pills are prepared by adding some specific types of auxiliary materials in certain proportions into the salbutamol sulfate and ambroxol hydrochloride serving as the active ingredients according to the conventional technique of pharmaceutical engineering.

The invention relates to a method for synchronously detecting five related substances in a compound ipratropium bromide solution for inhalation, and belongs to the technical field of drug quality determination methods. High performance liquid chromatography is adopted for detection, a chromatographic column with alkyl bonded silica gel is adopted as a filler, a phosphate buffer solution containingsodium heptanesulfonate is used as a mobile phase A, an organic phase is used as a mobile phase B, and a detection wavelength is 205-300nm. The detection method provided by the invention can effectively separate ipratropium bromide and salbutamol sulfate from other impurities, and has characteristics of simple operation, a comprehensive result, accuracy, reliability and strong specificity.

The invention provides alendronate sodium powder inhalation used for respiratory drug delivery and a preparation method and application thereof. Alendronate sodium powder inhalation includes single-component alendronate sodium micro powder and does not include auxiliary materials. In the production and preparation process of the alendronate sodium micro powder, other auxiliary materials or solvents are not involved, and alendronate sodium raw material medicine is directly smashed to prepare the alendronate sodium micro powder. The alendronate sodium powder inhalation can improve the breathing function of a chronic obstructive pulmonary disease (COPD) rat by about 40% and has a better effect than salbutamol sulfate with a common usage amount, and drug resistance of salbutamol sulfate and other beta2 receptor stimulants can be eliminated. The powder inhalation mainly makes sedimentation in the trachea, bronchia, bronchiole and other pulmonary respiratory ducts to directly take effect after drug-delivery inhalation, the diastolic function of the respiratory ducts becomes effective rapidly, and the drug effect lasts for a long time; the alendronate sodium powder inhalation enters pulmonary alveoli, is low in absorption and blood-entering amount, can avoid systematic side effects and is suitable for being developed to be a drug for treating COPD and asthma.

The invention discloses a preparation method of a salbutamol sulfate aerosol inhalation solution. The preparation method comprises the following steps: S1, adding 700 thousand ml of water for injection in a hermetic preparation tank for later use; S2, dissolving benzalkonium chloride with hot water for injection in advance, adding a benzalkonium chloride solution into a preparation barrel, and uniformly stirring; S3, adding water for nitrogen filling injection to 320 thousand ml and stirring for 15 minutes to be uniformly stirred; S4, adding water for nitrogen filling injection to full dose, and stirring for 15 minutes to be uniformly stirred; S5, filtering with a 0.35 mu m polyether sulfone microporous filtration membrane until the solution is clarified; S6, sampling and testing the content and pH value of an intermediate, covering the preparation barrel, and introducing nitrogen into the liquid medicine to protect; and S7, filtering the liquid medicine in a liquid storage barrel by a 0.22 mu m polyether sulfone microporous filtration membrane, sampling and examining visible foreign matters, and inputting the qualified visible foreign matters into a liquid storage container for encapsulation. The production quality of the salbutamol sulfate aerosol inhalation solution is effectively improved.

A process for preparing the micropowdered salbutamol sulfate includes mixing the solution of raw material containing salbutamol sulfate and acetone in filler layer of rotating filler bed, recrystallizing, filtering, washing and drying. Its advantages are high granularity uniformity, and controllable average granularity.

The invention discloses a process for preparing salbutamol sulfate orally disintegrating tablets. The process is characterized by comprising the steps of S1, weighing the main drug salbutamol sulfate and auxiliary materials according to a ratio; S2, mixing salbutamol sulfate with a lubricant to prepare mixed powder I; S3, mixing a filler with an internally added disintegrant, and adding an adhesive to prepare wet particles; S4, drying the wet particles to obtain dry particles; S5, conducting size stabilization on the dry particles; S6, adding an externally added disintegrant, the lubricant and the mixed powder I to the particles prepared in S5 to be mixed, so that total blended particles are obtained; S6, tabletting and weighing the total blended particles; and S7, packaging qualified tablets obtained in S6. The process is simple, the cost is low, large-scale production can be achieved, the problem that in the prior art, the stability of the thermosensitive crude drug salbutamol sulfate can be affected by high temperature is solved, and the hardness, the friability, the slice heavy difference and the disintegration time of the prepared salbutamol sulfate orally disintegrating tablets all meet requirements.

The invention discloses a salbutamol sulfate aerosol inhalation solution, and a preparation process and application thereof. The salbutamol sulfate solution is prepared from the following components:salbutamol sulfate, an osmotic pressure regulator, a pH regulator and water for injection, wherein the pH value of the salbutamol sulfate solution is 3.0 to 5.0. The salbutamol sulfate solution has good atomization performance and thermal stability.

The invention discloses a medicine composition for preventing and treating asthma, containing active components of 1 percent by weight of inactivated mycobacterium phlei F.U.36 and 1000-2000 percent by weight of salbutamol sulfate. The medicine composition is used for treating patients suffering from mild to moderate bronchial asthma and according with the 2006GINA diagnosis standard, measuring the lung function (FEV1%, PEF%) of the patients before and after treatment and the airway reactivity (PD20-FEV1), observing the symptoms of the patients and untoward effects of medicaments, and the like, and the difference of the FEV1% and the PEF% has no statistical significance as comparison before and after the treatment; the PD20-FEV1 after the treatment is obviously increased (p is smaller than 0.01) than that before the treatment; the provocation test negative conversion ratio is 88.9% (24 cases); and after the treatment, the symptoms of the patients are obviously relieved or disappear. Results show that the medicine composition can rapidly lower the airway reactivity and relieve the symptoms of asthma.

The invention provides a preparation method of salbutamol sulfate, and relates to the technical field of chemical synthesis. The preparation method of salbutamol sulfate comprises the following steps: (a) carrying out reaction on salicylic acid and a tert-butyl amino acetyl halogenating reagent under the action of a chlorinating agent to generate an intermediate 1; (b) reacting the intermediate 1 under the action of Lewis acid to generate an intermediate 2; (c) reacting the intermediate 2 under the action of an acid reagent to generate an intermediate 3; (d) reacting the intermediate 3 with a reducing agent under the action of a catalyst to generate salbutamol; and (e) reacting salbutamol with sulfuric acid to generate salbutamol sulfate. The raw materials are simple and easy to obtain, the reaction condition is mild, the reaction operation is simple, the reaction process is easier to control, and the safety coefficient is high; used raw materials, solvents and the like are environment-friendly; and the yield and purity of salbutamol sulfate are high, and a process route capable of industrially producing a product with higher quality is provided.

The invention relates to an oral compound pharmaceutic preparation for treating asthma, which contains tranilast shown as the formula (I) and salbutamol sulfate shown as the formula (II) or other pharmaceutically allowed active ingredients. The invention also relates to the application of compounds shown as formulas (I) and (II) or pharmaceutically allowed salts thereof in the preparation of an oral therapeutical agent for treating asthma.

The invention provides salbutamol sulfate oral cavity disintegration tablets and a preparation method thereof. The preparation method comprises the following steps of weighing a raw material namely salbutamol sulfate and auxiliary materials, performing screening, premixing the raw material with the auxiliary materials, and performing tabletting, wherein a powder direct tabletting technology is adopted for tabletting. The preparation method disclosed by the invention has the following advantages that the direct tabletting technology is adopted, fewer working procedures are adopted, equipment issimple, and commercial production is easy; after the particle diameter of the auxiliary materials is controlled, the fluidity and the compressibility of granules are greatly improved; after the technology is improved, the impurity level is lower than that of an original product; and the safety of a patient is improved, and potential safety hazards are avoided.

The invention discloses powder inhalation for treating respiratory system diseases such as chronic obstructive pulmonary diseases and asthma. The powder inhalation comprises all the tautomer, enantiomer, stereoisomer, acid anhydride, acid addition salt, basic salt, solvolyte, analogue and derivative of a first active ingredient - ipratropium, a second active ingredient - salbutamol, and one or more pharmaceutically acceptable carriers; wherein other pharmaceutically acceptable salt of salbutamol is selected from other salt of organic acid of salbutamol sulfate or salbutamol, and the mass ratio of the first active ingredient and the second active ingredient is 1:10 to 15:1; according to the ratio of the prescription, uniformly blending the ipratropium and the salbutamol and crushing to an average grain size of 1 to 5 Mum, crushing the dried carrier to an average grain size of 1 to 5 Mum, and filling the uniformly blended powder into a filling machine to produce the powder inhalation. The powder inhalation can directly act on the affected part, the efficacy presents quickly, and the use is convenient.

The invention relates to an ambroxol salbutamol lipid solid dispersion and a preparing method thereof, belonging to the field of medicinal preparations. The lipid solid dispersion contains ambroxol hydrochloride, salbutamol sulfate and butyl hydroxy anisol, a lipid carrier is a mixture of 25% of laurin, 30% of coconut oil, 15% of polyethylene glycol octanoic acid/caprin, 20% of vitamin E acetate and 10% of PEG200, a solid carrier is a mixture of 30% of aerosol and 70% of corn starch, and the ambroxol salbutamol lipid solid dispersion is stable in quality, obvious in effect and capable of effectively treating diseases of the respiratory system such as acute and chronic bronchitis and asthma.

The invention relates to an ambroxol salbutamol oral liquid and a preparing method thereof, belonging to the field of medicinal preparations. The oral liquid contains components such as ambroxol hydrochloride, salbutamol sulfate, propylene glycol, glycerol, methyl parahydroxybenzoats, sodium benzoate, mannitol, Steviosin and flavoring orange essence, is stable in quality, obvious in effect and capable of effectively treating diseases of the respiratory system such as acute and chronic bronchitis and asthma.

The invention provides a salbutamol sulfate solution for inhalation and a preparation method thereof. The prescription of the salbutamol sulfate solution comprises salbutamol sulfate, ipratropium bromide, an isoosmotic adjusting agent, a pH adjusting agent, sodium hyaluronate, carboxymethyl chitosan oligosaccharide and water for injection. The preparation process comprises the following steps: weighing, preparing a solution, adjusting the pH value, filtering, encapsulating, carrying out quality inspection and the like. According to the prescription and the preparation method, the stability ofthe preparation can be improved, meanwhile, the preparation has a good permeation effect, the salbutamol sulfate tolerance can be improved, and the preparation can better play a role.